Denali Therapeutics Inc. (DNLI) › Cash & EquivalentsDenali Therapeutics Inc. (DNLI) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2016-12-31: $39.85M2017-12-31: $218.38M2018-12-31: $77.12M2019-12-31: $79.45M2020-12-31: $507.14M2021-12-31: $293.48M2022-12-31: $218.04M2023-12-31: $127.11M2024-12-31: $174.96M2025-12-31: $205.33M$205.33M2016-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$205.33M+17.4%2026-02-26Balance as of period end2024-12-31$174.96M+37.6%2026-02-26Balance as of period end2023-12-31$127.11M-41.7%2025-02-27Balance as of period end2022-12-31$218.04M-25.7%2024-02-28Balance as of period end2021-12-31$293.48M-42.1%2023-02-27Balance as of period end2020-12-31$507.14M+538.3%2022-02-28Balance as of period end2019-12-31$79.45M+3.0%2021-02-26Balance as of period end2018-12-31$77.12M-64.7%2020-02-27Balance as of period end2017-12-31$218.38M+448.0%2020-02-27Balance as of period end2016-12-31$39.85M—2019-03-12Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)